Q2 EPS Estimates for Vera Therapeutics Lifted by Wedbush

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Research analysts at Wedbush boosted their Q2 2025 earnings per share estimates for shares of Vera Therapeutics in a research note issued to investors on Monday, June 9th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.70) per share for the quarter, up from their previous estimate of ($0.71). Wedbush has a "Neutral" rating and a $26.00 price target on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics' Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.19) EPS, Q1 2026 earnings at ($0.94) EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.08) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($3.95) EPS, FY2027 earnings at ($3.34) EPS, FY2028 earnings at ($1.94) EPS and FY2029 earnings at ($1.01) EPS.

VERA has been the topic of several other reports. Scotiabank restated an "outperform" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. HC Wainwright restated a "buy" rating and set a $85.00 target price (up from $75.00) on shares of Vera Therapeutics in a report on Monday, June 2nd. JPMorgan Chase & Co. decreased their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research note on Tuesday, March 4th. Guggenheim reaffirmed a "buy" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. Finally, Cantor Fitzgerald decreased their price target on shares of Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Vera Therapeutics presently has a consensus rating of "Buy" and an average target price of $65.00.

Vera Therapeutics Trading Up 1.0%

Vera Therapeutics stock traded up $0.22 during trading hours on Wednesday, reaching $22.74. 1,306,850 shares of the company's stock traded hands, compared to its average volume of 949,096. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. Vera Therapeutics has a fifty-two week low of $18.53 and a fifty-two week high of $51.61. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of -8.71 and a beta of 1.13. The firm's 50 day moving average is $22.52 and its 200-day moving average is $30.62.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter in the previous year, the company earned ($0.56) EPS.

Institutional Investors Weigh In On Vera Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Huntington National Bank acquired a new stake in shares of Vera Therapeutics during the fourth quarter worth $26,000. AlphaQuest LLC acquired a new stake in shares of Vera Therapeutics during the fourth quarter worth $34,000. GF Fund Management CO. LTD. acquired a new stake in shares of Vera Therapeutics during the fourth quarter worth $56,000. Quarry LP lifted its holdings in shares of Vera Therapeutics by 25.0% during the first quarter. Quarry LP now owns 2,500 shares of the company's stock worth $60,000 after buying an additional 500 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its holdings in shares of Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after buying an additional 639 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.